NASHVILLE'S TOP 30 UNDER 30 PROFESSIONAL AND PHILANTHROPIC LEADERS NAMED FOR 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
7 hours ago
- Politico
Canada courts Arctic allies to counter Russia
Canada's Arctic defense strategy is shifting away from a bilateral relationship with the United States toward a broader NATO framework. With Sweden and Finland joining NATO after Russia's February 2022 invasion of Ukraine — and in the wake of Trump's tariff attacks — Ottawa is widening its foreign policy focus to align with NATO as the foundation of its Arctic security. Busch said she welcomed a strategic partnership, 'focusing on security and defense, investment and competitiveness, digital innovation and energy raw materials.' Joly name-checked Canadian ties to Saab, as well as to Sweden tech giants Ericsson and ABB (Asea Brown Boveri). 'We have the crown jewels of the private sector of Sweden already in our country, but we want to do more,' the minister said. On Tuesday, Canada added one more jewel when Roshel, a Canadian manufacturer of armored vehicles, signed a 'strategic partnership agreement' with Swedish steel producer Swebor. Roshel said in a statement that the partnership will 'establish Canada's first facility dedicated to production of ballistic-grade steel' — a key ingredient in military vehicles. Earlier in the trip, Joly visited Saab, the Swedish manufacturer of the Gripen — at one time a runner-up on Canada's shortlist to replace its aging fleet of CF-18s. Lockheed Martin won that contract, and will deliver 16 of the stealth fighters so far. Joly is joined on this week's trip by Stephen Fuhr, Canada's new secretary of state for defense procurement, as Ottawa contemplates whether it will buy 72 more F-35s. Swedish Deputy Prime Minister Ebba Busch (left) welcomes Canadian Industry Minister Mélanie Joly to Stockholm on Monday. | Jonas Akstromer/TT News Agency/AFP via Getty Images Later in the week, Joly is to cut the ribbon on a joint Finnish-Canadian shipbuilding venture that will begin manufacturing a new fleet of icebreakers for Canada's Coast Guard. Meanwhile in Europe, Foreign Affairs Minister Anita Anand was scheduled to meet with Finland President Alexander Stubb on Tuesday. The tête-à-tête follows Stubb's appearance at the White House Monday alongside other European leaders, supporting Ukrainian President Volodymyr Zelenskyy in the Trump-brokered negotiation with Russia's Vladimir Putin to end the war in Eastern Europe.
Yahoo
5 days ago
- Yahoo
2 Growth Stocks That Are No-Brainer Buys Right Now
Key Points Vertex Pharmaceuticals' recent dip presents an excellent buying opportunity, given its promising prospects. Netflix is performing exceedingly well, and the streaming giant has every reason to continue doing so. 10 stocks we like better than Vertex Pharmaceuticals › Over the past five years, the stock market has endured a pandemic and the economic issues that followed, along with inflationary pressures, geopolitical tensions, trade wars, and other macroeconomic challenges. Despite all that, equities have performed well. Though we can't predict the future in great detail, we can be confident that stocks will generally continue to deliver strong returns over the long run. And one of the best ways to cash in on that is to invest in stocks that can exceed the market's performance. Two that look particularly attractive are Vertex Pharmaceuticals (NASDAQ: VRTX) and Netflix (NASDAQ: NFLX). Here's why these two stocks appear to be great options for investors. 1. Vertex Pharmaceuticals Vertex Pharmaceuticals' shares recently dropped following a clinical setback. The company's VX-993, a potential treatment for acute pain, did not impress in a phase 2 study. Management also stated that it would no longer pursue one promising indication for its new pain medicine, Journavx, following feedback from regulators. The market responded by selling off the stock. However, Vertex's overall business remains strong, as evidenced by its second-quarter results. Revenue jumped by 12% year over year to $2.96 billion. Vertex is still the only company that markets medicines for cystic fibrosis (CF), a rare lung disease. The company's most recent launch in this market, Alyftrek, which earned approval in the U.S. in December, is already making solid headway; it generated $156.8 million in sales in the second quarter. Vertex's monopoly in CF grants it significant pricing power, which is one of the best parts of the business and makes the stock so attractive. The company's newer non-CF launches, Journavx and Casgevy -- the latter of which treats two rare blood diseases -- aren't yet contributing significantly to its sales, but that should change over time. Furthermore, Vertex has some highly promising late-stage assets. One of them is zimislecel, an investigational therapy for type 1 diabetes; it could help eliminate severe hypoglycemic events, potentially life-threatening side effects of the disease. Vertex plans to file regulatory applications for zimislecel next year. That's to say nothing of various early-stage projects Vertex is working on. Recent developments were not great for the company, so it's not that surprising that the stock fell significantly. Even so, Vertex Pharmaceuticals has faced similar one-day drops before; it usually recovers thanks to solid financial results and strong clinical and regulatory progress. Expect the biotech to do the same this time around. Vertex looks like a strong buy following its recent dip. 2. Netflix Netflix has been on fire over the past few years. Revenue growth has been strong, and the trend continues. In the second quarter, the top line increased by 15.9% year over year to $11.1 billion. The company has experienced profitable growth recently -- it's growing not only revenue, but also profit, margins, and free cash flow. The entertainment giant continues to benefit from the switch to streaming, but there is still plenty of white space ahead. According to management, the company still expects hundreds of millions of people to sign up on its platform. And subscriber growth isn't the only thing that will drive better results. Increased engagement, as measured by viewing hours, can help boost the company's relatively new advertising business. Netflix estimates that it has only captured about 6% of its revenue potential, leaving it with massive long-term opportunities as streaming continues to displace cable. Competition might be an issue, but thanks to its brand name and network effects, Netflix has built a solid moat. Valuation is another problem some investors might point to here. The stock is trading at around 48 times forward earnings, well above the average for communication services stocks, which is 20. However, Netflix is changing the entertainment world. The company might not realize its master plan for many years, perhaps even several decades, given the massive worldwide addressable market. That's what makes its stock so attractive. For those who want to go along for the ride, Netflix's shares remain a buy even at current levels. Should you invest $1,000 in Vertex Pharmaceuticals right now? Before you buy stock in Vertex Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Vertex Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* Now, it's worth noting Stock Advisor's total average return is 1,071% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Netflix and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. 2 Growth Stocks That Are No-Brainer Buys Right Now was originally published by The Motley Fool Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Insider
09-08-2025
- Business Insider
UBS Sticks to Their Hold Rating for Cf Industries Holdings (CF)
UBS analyst Joshua Spector maintained a Hold rating on Cf Industries Holdings yesterday and set a price target of $101.00. The company's shares closed today at $80.88. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Spector is a 2-star analyst with an average return of -0.1% and a 49.25% success rate. Spector covers the Basic Materials sector, focusing on stocks such as Eastman Chemical, Methanex, and TRONOX. In addition to UBS, Cf Industries Holdings also received a Hold from Oppenheimer's Kristen Owen in a report issued yesterday. However, today, TR | OpenAI – 4o reiterated a Buy rating on Cf Industries Holdings (NYSE: CF). CF market cap is currently $14.56B and has a P/E ratio of 11.75. Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CF in relation to earlier this year. Most recently, in June 2025, Bert Frost, the EVP,Sales,MktDev&Supply Chain of CF sold 5,000.00 shares for a total of $503,500.00.
